Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

It features thorough molecular simulations of the receptor within its native membrane environment, complemented by ensemble virtual screening that considers its conformational mobility. For dimeric or oligomeric receptors, the full functional complex is constructed, and tentative binding sites are determined on and between the subunits to cover the entire spectrum of potential mechanisms of action.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P27930

UPID:
IL1R2_HUMAN

ALTERNATIVE NAMES:
CD121 antigen-like family member B; CDw121b; IL-1 type II receptor; Interleukin-1 receptor beta; Interleukin-1 receptor type II

ALTERNATIVE UPACC:
P27930; D3DVJ5; Q6LCE6; Q9UE68

BACKGROUND:
The Interleukin-1 receptor type 2 (IL-1R2), recognized by alternative names such as CDw121b and Interleukin-1 receptor beta, is pivotal in immune regulation. It acts by competitively binding to IL1B, thus preventing its interaction with IL1R1 and modulating the cellular response to inflammation. The secreted form of IL-1R2, in conjunction with IL1RAP, forms a complex that serves as a dominant mechanism for neutralizing IL1B, highlighting its significance in immune response modulation.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Interleukin-1 receptor type 2 offers promising avenues for developing novel therapeutic interventions aimed at controlling inflammatory responses.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.